SYNAPS Dx Resolves Alzheimer’s Disease Diagnostic Dilemma: White Paper Documents Improved Diagnostic Pathway

SYNAPS Dx (SDx), a privately held company focused on the research, development and commercialization of a diagnostic test for Alzheimer’s disease (AD), is pleased to announce the release of its white paper, “Resolving a Diagnostic Dilemma.” This paper is a timely, authoritative document articulating a simplified diagnostic pathway to identify AD in the community primary care and neurology settings. Addressing some of the most pressing issues to elevate the current diagnostic approach, this potential diagnostic pathway leverages existing guidance to identify the right candidates for prescribing drugs to treat AD and for those without AD, it informs care plans to address modifiable risk factors of dementia.

“With the introduction of newly approved drugs to treat AD such as lecanemab, there is growing need to accurately identify the appropriate patients for prescribing these drugs, given their cost and risk/benefit profiles,” says Frederick Huie, M.D., medical director, CVS/Aetna and SDx advisory council member. “With studies showing that 40% of dementia cases may be preventable by addressing modifiable risk factors, a more accurate diagnosis of AD in the community setting can inform care plans to address comorbid conditions behind the dementia symptoms.”